Summit Therapeutics Inc.

NasdaqGM:SMMT Stock Report

Market Cap: US$12.4b

Summit Therapeutics Management

Management criteria checks 3/4

Summit Therapeutics' CEO is Bob Duggan, appointed in Jul 2022, has a tenure of 3.67 years. directly owns 73.52% of the company’s shares, worth $9.15B. The average tenure of the management team and the board of directors is 2.6 years and 5.3 years respectively.

Key information

Bob Duggan

Chief executive officer

US$158.6k

Total compensation

CEO salary percentagen/a
CEO tenure3.7yrs
CEO ownership73.5%
Management average tenure2.6yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Late Stage Oncology Footprint Will Transform This Single Asset Into A Global Cancer Franchise

Catalysts About Summit Therapeutics Summit Therapeutics is a biopharmaceutical company focused on developing and commercializing ivonescimab for solid tumor cancers. What are the underlying business or industry changes driving this perspective?

Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade)

Jan 30

Summit Therapeutics: New Ivonescimab Data Raise Concerns

Apr 26

Summit Therapeutics: Not Pharmacyclics, Not Yet

Apr 12

Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)

Mar 28

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program

Feb 24

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

Jan 18

The Play On Summit Therapeutics

Jan 05

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Dec 02

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Oct 04

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Sep 19

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Sep 09

Summit Therapeutics May Have Further Upside From Here

Aug 03

Summit Therapeutics Stock: Plunging Despite A Win?

May 31

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

May 06

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Jan 30

Summit Therapeutics slips on plans to terminate study for lead candidate

Oct 04

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

CEO

Bob Duggan (81 yo)

3.7yrs
Tenure
US$158,613
Compensation

Mr. Robert W. Duggan, also known as Bob, had been an Interim Principal Financial Officer at Summit Therapeutics Inc. since July 02, 2021. He served as the Co-Chief Executive Officer at Summit Therapeutics...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Duggan
Co-CEO & Executive Chairman3.7yrsUS$158.61k73.52%
$ 9.2b
Mahkam Zanganeh
Co-CEO, President & Director3.7yrsUS$1.16m4.65%
$ 578.4m
Manmeet Soni
COO, CFO & Director2.4yrsUS$4.77m0.40%
$ 49.3m
Kay Davies
Co-Founderno datano datano data
Bhaskar Anand
Chief Accounting Officer1.9yrsno data0.021%
$ 2.6m
Nathan LiaBraaten
Senior Director of Investor Relationsno datano datano data
Dave Gancarz
Chief Business & Strategy Officerno datano datano data
Wang Fong
Chief Biometrics Officer5.2yrsno datano data
Urte Gayko
Chief Regulatory3.9yrsUS$609.86kno data
Allen Yang
Head of R&D Strategy2.6yrsno datano data
Laura Q. Chow
Senior Vice President of Clinical Development2.3yrsno datano data
Robert LaCaze
Chief Commercial Officer1yrno datano data
2.6yrs
Average Tenure
56yo
Average Age

Experienced Management: SMMT's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Duggan
Co-CEO & Executive Chairman6.3yrsUS$158.61k73.52%
$ 9.2b
Mahkam Zanganeh
Co-CEO, President & Director5.3yrsUS$1.16m4.65%
$ 578.4m
Manmeet Soni
COO, CFO & Director6.3yrsUS$4.77m0.40%
$ 49.3m
Kay Davies
Co-Founderno datano datano data
Kenneth Clark
Lead Independent Director4.4yrsUS$3.85m0%
$ 0
Marcel van den Heuvel
Member of Scientific Advisory Boardno datano datano data
Francesco Muntoni
Member of Scientific Advisory Boardno datano datano data
Roger Patient
Member of Scientific Advisory Boardno datano datano data
Jeffrey Huber
Independent Director1.8yrsUS$1.55m0.0065%
$ 804.1k
Edith Sim
Member of Scientific Advisory boardno datano datano data
Bob Sim
Member of Scientific Advisory boardno datano datano data
Derek Stemple
Member of Scientific Advisory boardno datano datano data
5.3yrs
Average Tenure
61.5yo
Average Age

Experienced Board: SMMT's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/12 07:38
End of Day Share Price 2026/03/11 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Summit Therapeutics Inc. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Yun ZhongBrean Capital Historical (Janney Montgomery)
Timothy ChiangBTIG